A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting

Pfizer

Status: Completed

Conditions: Breast Neoplasms

Study type: Observational

Funder types: Industry

Identifiers

NCT05478590

A5481177

Details and patient eligibility

About

The study is descriptive and aims to characterize the treatment patterns of advanced breast cancer in Poland in the real-world data setting. The main goals are to assess the current treatment patterns of hormone receptor-positive (HR+) Human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer and their changes in clinical practice and relate them to patients' demographics, disease characteristics, type of other therapies used in patients as well as disease progression and visceral crisis occurrence.

Enrollment: 440 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients with histologically diagnosed advanced breast cancer (with locoregional recurrence not eligible for radical local treatment or with distant metastases)
• Patient has a documented hormone (estrogen and/or progesterone) receptor expression and lack of HER2 receptor overexpression or lack of HER2 gene amplification (HR+/HER2- breast cancer subtype)
• Patient had no prior treatment for advanced breast cancer
• Patient has no symptomatic metastases to the central nervous system
• There is no other malignancies in patient requiring active treatment
• Patient is without co-occurring other malignancies treated with palliative assumption

Exclusion criteria

• Parallel patient's participation in any other clinical trial at the time when the decision over the advanced breast cancer treatment was made or up to 30 days before it.